Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms
暂无分享,去创建一个
[1] S. Permpongkosol,et al. Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. , 2010, The journal of sexual medicine.
[2] C. Roehrborn,et al. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment , 2010, BJU international.
[3] A. Tuncel,et al. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction , 2010, World Journal of Urology.
[4] M. Kuczyk,et al. Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. , 2009, Urology.
[5] A. Bechara,et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. , 2008, The journal of sexual medicine.
[6] C. Stief,et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. , 2008, European urology.
[7] M. Elhilali,et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3‐year experience in real‐life practice , 2008, BJU international.
[8] C. Roehrborn,et al. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia , 2007, International Journal of Impotence Research.
[9] S. Madersbacher,et al. Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment , 2007, International Journal of Impotence Research.
[10] S. Kaplan,et al. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. , 2007, European urology.
[11] K. McVary,et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. , 2007, The Journal of urology.
[12] J. Mulhall,et al. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. , 2006, The journal of sexual medicine.
[13] S. Kaplan,et al. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. , 2006, Urology.
[14] K. McVary. BPH: epidemiology and comorbidities. , 2006, The American journal of managed care.
[15] C. Carson. Combination of phosphodiesterase‐5 inhibitors and α‐blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? , 2006, BJU international.
[16] T. Wilt,et al. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. , 2005, Urology.
[17] R. Kloner,et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. , 2004, The Journal of urology.
[18] J. Reynard. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? , 2004, Current opinion in urology.
[19] M. Wyllie,et al. Safety and efficacy of alfuzosin 10 mg once‐daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double‐blind, placebo‐controlled studies , 2003, BJU international.
[20] E. Kulinskaya,et al. Sildenafil influences lower urinary tract symptoms , 2002, BJU international.
[21] U. Jonas,et al. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. , 2001, The Journal of urology.
[22] C. Roehrborn,et al. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. , 2001, Urology.
[23] J. Kozlowski,et al. Intrinsic and extrinsic factors controlling benign prostatic growth , 1997, The Prostate.
[24] J. Robinson. The lower urinary tract. , 1982, British journal of clinical pharmacology.